High-resolution analysis of alterations in medullary thyroid carcinoma genomes

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Flicker, Karin ^a   Ulz, Peter ^a   Höger, Harald ^b   Zeitlhofer, Petra ^c   Haas, Oskar A ^c   Behmel, Annemarie ^a   Buchinger, Wolfgang ^d   Scheuba, Christian ^b   Niederle, Bruno ^b   Pfragner, Roswitha ^a   Speicher, Michael R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Medgenat GmbH   (Austria)

^d KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

array CGH; chromosomal instability; genomic imbalances; medullary thyroid carcinoma; RET gene

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 4Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHROMOSOME MAP; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; FEMALE; GENE FUNCTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE RET; PRIMARY TUMOR; PRIORITY JOURNAL; SCID MOUSE; SOMATIC MUTATION; THYROID CARCINOMA;

ANIMALS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84861614029     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26494     Document Type: Article

References (38)

1. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M,. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008; 4: 22-32.
2. Ponder BA,. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 1999; 59: 1736s, 1741s; discussion 1742s.
3. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA, Jr,. Medullary thyroid cancer: management guidelines of the american thyroid association. Thyroid 2009; 19: 565-612.
4. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G,. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-6.
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L,. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
6. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH,. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995; 267: 381-3.
7. Cerrato A, De Falco V, Santoro M,. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009; 43: 143-55.
8. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, Nederlof PM,. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006; 94: 333-7.
9. Pfragner R, Hofler H, Behmel A, Ingolic E, Walser V,. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 1990; 50: 4160-6.
10. Pfragner R, Wirnsberger GH, Ingolic E, Niederle B,. Medullary thyroid carcinomas in cell culture - models for future therapies. Wien Klin Wochenschr 2002; 114: 279-83.
11. Pfragner R, Voglauer R, Stadler G, Stift A, Friedl J, Niederle B, Gnant M,. Medullary thyroid carcinoma cell lines for dendritic cell based immunotherapy. J Int Med 2004; 255: P1007.
12. Stadler G, Wieser M, Streubel B, Stift A, Friedl J, Gnant M, Niederle B, Beham A, Katinger H, Pfragner R, Grillari J, Voglauer R,. Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma. Eur J Cancer 2008; 44: 866-75.
13. Pfragner R,. Human medullary thyroid carcinoma-cell lines as model systems to study drug resistance. In Vitro Cell Dev Biol 2000; 36: 8.
14. Pfragner R, Wirnsberger G,. Cultivation of parafollicular C-cells from medullary thyroid carcinomas. In:, Doyle A, Griffiths JB, Newell DG, eds. Cell and tissue culture: laboratory procedures. Chichester, module: John Wiley, 1996. 1-16.
15. Pfragner R, Behmel A, Ingolic E, Wirnsberger H,. Culture of human neuroendocrine tumor cells. In:, Pfragner R, Freshney RI, eds. Culture of specialized cells. Hoboken: John Wiley, 2004. 373-403.
16. Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R, Brostjan C, Riss S, Niederle B, Gnant M, et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009; 21: 1585-92.
17. Pfragner R, Wirnsberger G, Behmel A, Wolf G, Passath A, Ingolic E, Adamiker D, Schauenstein K,. New continuous cell line from human medullary thyroid carcinoma: SINJ. phenotypic analysis and in vivo carcinogenesis. Int J Oncol 1993; 2: 831-6.
18. Pfragner R, Wirnsberger G, Behmel A, Niederle B,. Multiple endocrine neoplasia (MEN2A) approached by cell culture. J Exper Clin Cancer Res 1995; 14: 200-1.
19. Geigl JB, Uhrig S, Speicher MR,. Multiplex-fluorescence in situ hybridization for chromosome karyotyping. Nat Protoc 2006; 1: 1172-84.
20. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ, Hoppener JW,. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Res 2008; 68: 1329-37.
21. Drosten M, Putzer BM,. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006; 3: 564-74.
22. Messina M, Robinson BG,. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007; 3: 290-301.
23. Cranston AN, Ponder BA,. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Res 2003; 63: 4777-80.
24. Herrmann M,. Standard and molecular cytogenetics of endocrine tumors. Am J Clin Pathol 2003; 119 Suppl: S17-38.
25. Wurster-Hill DH, Noll WW, Bircher LY, Pettengill OS, Grizzle WA,. Cytogenetics of medullary carcinoma of the thyroid. Cancer Genet Cytogenet 1986; 20: 247-53.
26. Scappaticci S, Arrigoni G, Capra E, Maraschio P, Fraccaro M,. Cytogenetics of multiple endocrine neoplasia syndromes. I. Two different, unique clonal chromosome changes in a medullary thyroid carcinoma and in a C-cell thyroid hyperplasia. Cancer Genet Cytogenet 1992; 59: 51-3.
27. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H,. DNA copy number changes in thyroid carcinoma. Am J Pathol 1999; 154: 1539-47.
28. Frisk T, Zedenius J, Lundberg J, Wallin G, Kytola S, Larsson C,. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome. Int J Oncol 2001; 18: 1219-25.
29. Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Roher HD, Delbridge L, Robinson BG,. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1866-72.
30. Ye L, Santarpia L, Cote GJ, El-Naggar AK, Gagel RF,. High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 4367-72.
31. Pinkel D, Albertson DG,. Array comparative genomic hybridization and its applications in cancer. Nat Genet 2005; 37 Suppl: S11-7.
32. Berger CL, de Bustros A, Roos BA, Leong SS, Mendelsohn G, Gesell MS, Baylin SB,. Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. J Clin Endocrinol Metab 1984; 59: 338-43.
33. Leong S, Horoszewicz JS, Shimaoka K, Friedman M, Kawinski E, Song MJ, Chu TM, Baylin S, Mirand EA,. A new cell line for study of human medullary thyroid carcinoma. In:, Andreoli M, Monaco M, Robbins J, eds. Advances in thyroid neoplasia. Rome: Field Educational Italia, 1981: 95-108.
34. Cooley LD, Elder FF, Knuth A, Gagel RF,. Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genet Cytogenet 1995; 80: 138-49.
35. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, et al. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest 2007; 30: RC31-4.
36. Azofeifa J, Fauth C, Kraus J, Maierhofer C, Langer S, Bolzer A, Reichman J, Schuffenhauer S, Speicher MR,. An optimized probe set for the detection of small interchromosomal aberrations by use of 24-color FISH. Am J Hum Genet 2000; 66: 1684-8.
37. Wang Z, Gerstein M, Snyder M,. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10: 57-63.
38. Meyerson M, Gabriel S, Getz G,. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-96.